Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dr. John Wallace
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by themagicboxon Sep 09, 2020 7:53pm
134 Views
Post# 31531071

RE:RE:RE:RE:RE:Dr. John Wallace

RE:RE:RE:RE:RE:Dr. John WallaceI can relate man. Im just curious why they didnt power the 150mg from the get go for statistical significance. Was it money? was it taking too long? Recruiting issues? They didnt really address this issue head on. They definitely mucked up on many fronts. 

But going off of MUGs last comment, they want to have the least amount of SEs at the minimal/maximal analgesic efficacy, so really its an optimization question from this point.


Marky1 wrote: Nice to hear from you Magic! Missed your comments...always great reading...No, I am still very positive on ATE....I believe in the chemistry, the H2S technology, in management...but...i was extremely disappointed by the June PR bringing to SP from .89$ to under .60$....I feel that they really mucked it up....They should, I think, just left off the 150mg dosage...200 mg and 250mg were that's all that was needed..why bring something that was not statistically significant into the equation..Hopefully the new NY company, Stern, will do a better job aimed at institutional, retail audience
IMHO...
take care folks
Jean Marc


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities